Assay Harmonization and Use of Biological Standards To Improve the Reproducibility of the Hemagglutination Inhibition Assay: a FLUCOP Collaborative Study-Reference-Cited by-全球学者库

Assay Harmonization and Use of Biological Standards To Improve the Reproducibility of the Hemagglutination Inhibition Assay: a FLUCOP Collaborative Study

Published:2021-08-25 Issue:4 Volume:6 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

Waldock Joanna¹,Zheng Lingyi²,Remarque Edmond J.³,Civet Alexandre⁴,Hu Branda²,Jalloh Sarah Lartey⁵,Cox Rebecca Jane⁵,Ho Sammy⁶,Hoschler Katja⁶,Ollinger Thierry⁷,Trombetta Claudia Maria⁸,Engelhardt Othmar G.¹,Caillet Catherine²^ORCID

Affiliation:

1. National Institute for Biological Standards and Control, Potters Bar, United Kingdom

2. Sanofi Pasteur, Swiftwater, Pennsylvania, USA

3. Biomedical Primate Research Centre, Rijswijk, The Netherlands

4. Quinten, Paris, France

5. Influenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway

6. Public Health England, Colindale, United Kingdom

7. GSK, Wavre, Belgium

8. University of Siena, Department of Molecular and Developmental Medicine, Siena, Italy

Abstract

The hemagglutination inhibition (HAI) assay is the most commonly used serology assay to detect antibodies from influenza vaccination or influenza virus infection. This assay has been used for decades but requires improved standardization of procedures to provide meaningful data.

Funder

Innovative Medicines Initiative Joint Undertaking

European Union Seventh Framework Programme

European Federation of Pharmaceutical Industries and Associations

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mSphere.00567-21

Reference15 articles.

1. World Health Organization. 2018. Influenza (seasonal). WHO fact sheet. World Health Organization Geneva Switzerland. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).

2. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

3. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future

4. Reproducibility of Serologic Assays for Influenza Virus A (H5N1)

5. Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine;Emerging Microbes & Infections;2023-08-28

2. Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study;Frontiers in Immunology;2023-04-18

3. H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials;Frontiers in Immunology;2023-04-06

4. An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study;Frontiers in Immunology;2023-02-28

5. Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise;mBio;2022-08-30